Best Book for Men Newly Diagnosed with Prostate Cancer
This book excels in helping men decide about prostate cancer (PCa) treatment. Co-written by an excellent medical oncologist specializing in PCa (MOSPC), it contains authoritative information, e.g.:
There are three basic categories of PCa--Low-, Intermediate-, and High-Risk.
High-Risk, also known as "aggressive," should be treated aggressively whereas Low-Risk often can be safely managed with no treatment.
A doctor refers a man to a urologist because of an abnormal PSA test and/or digital rectal examination (DRE): The urologist biopsies the man's prostate and finds PCa. Typically, the man views PCa as a death sentence, panics, and feels pressured to get rid of it immediately. He avoids delaying for second opinions and agrees quickly to have the urologist cut out his prostate (radical prostatectomy or RP)--an aggressive treatment.
Of the 50,000 RPs done in the USA every year, more than 40,000 were not necessary. That is, the vast majority of PCa patients would have lived as long without having their prostates removed.
RP is no longer the most effective treatment for PCa. Radiation therapy (RT), another aggressive treatment, has evolved into being at least as effective.
Another type of PCa doctor is a medical oncologist, who is trained to treat all cancers. Their training in PCa treatment focuses only on advanced disease. Early-stage disease is left for urologists.
Medical oncologists treat some PCa patients with testosterone inactivating pharmaceuticals (TIP, also known as "hormone blockade" or "androgen deprivation therapy"). TIP has its side effects but, unlike RP, RT, or cryotherapy, the side effects are often reversible when the doctor stops the TIP.
Only a minority of urologists are as skilled as MOSPCs in providing TIP.
Of the more than 10,000 medical oncologists in the USA only less than 100 are MOSPCs.
MOSPCs often do more comprehensive evaluations than some urologists. In addition to PSAs, DREs, PSA velocity calculations, and PSA density calculations, they may use spectrographic endorectal MRI (S-MRI) scans, color doppler ultrasound scans, and PCA-3 tests to assess the risk-level. The tests also help monitor PCa (called "active surveillance" or AS).
The evaluation also helps determine whether an immediate initial biopsy is needed. If the patient has had a biopsy, the evaluation may reduce the number of repeat biopsies needed for AS.
Chapters by Blum, a patient of his co-author, illustrate the benefits received by a patient who learns about PCa, finds the right doctor, and avoids blindly following doctors' advice. Blum's story of his 20-year PCa journey is likely to empower more patients to take charge of theirs.
Blum went overseas to Holland for a Combidex MRI because it was only available there. My guess is that less than 10 percent of PCa patients are able to take the time off and/or pay for out-of-state/country trips for expert help. The book does not acknowledge this obstacle.
Snatchers adds greatly to the meager literature on how MOSPCs help patients decide on a treatment and care for Low-Risk patients.
The list of MOSPCs might help patients find the right doctor.
My qualifications: participating in PCa online forums; leading PCa support group discussions; seeing the MOSPC co-author of Snatchers every three months for nine years; undergoing biopsies, S-MRIs, Color Dopplers; avoiding aggressive treatment; writing my PCa s
2 out of 2 people found this review helpful.
Was this review helpful? Yes NoThank you for your feedback.
Report this reviewThank you, this review has been flagged.